GLP‐1 Agonists for Pediatric Psychopharmacology: Opportunities and Cautions
ABSTRACT Glucagon‐like peptide‐1 agonists (GLP‐1A) are increasingly prescribed to treat obesity and type 2 diabetes mellitus in children and adolescents. Emerging evidence suggesting neuropsychiatric effects presents an opportunity for pediatric psychopharmacology but requires careful consideration...
Saved in:
Main Authors: | Michael Bartkoski, Ethan A. Poweleit, Stephani L. Stancil |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-06-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.70262 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Incretin-Based Treatment Strategy - GLP-1 Receptor Agonists (GLP-1R) or So-Called Incretin Mimetics
by: Perusicova, Jindra, et al.
Published: (2011) -
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
by: Giulia Migliorisi, et al.
Published: (2025-07-01) -
Hormonal modulation, mitochondria and Alzheimer’s prevention: the role of GLP-1 agonists and estrogens
by: Fernando Lizcano, et al.
Published: (2025-06-01) -
Role of physical activity in GLP-1 receptor agonist therapy for obesity treatment
by: Łukasz Zdziebkowski, et al.
Published: (2025-07-01) -
GLP-1 agonists in anaesthetic practice - a review of clinical data and recommendations
by: Natalia Pokrywka, et al.
Published: (2025-07-01)